Background Malaria remains a serious health problem because resistance develops to all currently used drugs when their parasite targets mutate. Novel antimalarial drug targets are urgently needed to reduce global morbidity and mortality. Our prior results suggested that inhibiting erythrocyte Gs signaling blocked invasion by the human malaria parasite Plasmodium falciparum. Methods and Findings We investigated the erythrocyte guanine nucleotide regulatory protein Gs as a novel antimalarial target. Erythrocyte “ghosts” loaded with a Gs peptide designed to block Gs interaction with its receptors, were blocked in β-adrenergic agonist-induced signaling. This finding directly demonstrates that erythrocyte Gs is functional and that propranolol, an antagonist of G protein–coupled β-adrenergic receptors, dampens Gs activity in erythrocytes. We subsequently used the ghost system to directly link inhibition of host Gs to parasite entry. In addition, we discovered that ghosts loaded with the peptide were inhibited in intracellular parasite maturation. Propranolol also inhibited blood-stage parasite growth, as did other β2-antagonists. β-blocker growth inhibition appeared to be due to delay in the terminal schizont stage. When used in combination with existing antimalarials in cell culture, propranolol reduced the 50% and 90% inhibitory concentrations for existing drugs against P. falciparum by 5- to 10-fold and was also effective in reducing drug dose in animal models of infection. Conclusions Together these data establish that, in addition to invasion, erythrocyte G protein signaling is needed for intracellular parasite proliferation and thus may present a novel antimalarial target. The results provide proof of the concept that erythrocyte Gs antagonism offers a novel strategy to fight infection and that it has potential to be used to develop combination therapies with existing antimalarials.
References
[1]
Varmus H, Klausner R, Zerhouni E, Acharya T, Daar AS, et al. (2003) Grand challenges in global health. Science 302: 398–399.
[2]
Miller LH, Baruch DI, Marsh K, Doumbo OK (2002) The pathogenic basis of malaria. Nature 415: 673–679.
[3]
Murphy SC, Hiller NL, Harrison T, Lomasney JW, Mohandas N, et al. (2006) Lipid rafts and malaria parasite infection of erythrocytes. Mol Membr Biol 23: 81–88.
[4]
Murphy SC, Samuel BU, Harrison T, Speicher KD, Speicher DW, et al. (2004) Erythrocyte detergent-resistant membrane proteins: Their characterization and selective uptake during malarial infection. Blood 103: 1920–1928.
[5]
Samuel BU, Mohandas N, Harrison T, McManus H, Rosse W, et al. (2001) The role of cholesterol and glycosylphosphatidylinositol-anchored proteins of erythrocyte rafts in regulating raft protein content and malarial infection. J Biol Chem 276: 29319–29329.
[6]
Lauer S, VanWye J, Harrison T, McManus H, Samuel BU, et al. (2000) Vacuolar uptake of host components, and a role for cholesterol and sphingomyelin in malarial infection. EMBO J 19: 3556–3564.
[7]
Harrison T, Samuel BU, Akompong T, Hamm H, Mohandas N, et al. (2003) Erythrocyte G protein-coupled receptor signaling in malarial infection. Science 301: 1734–1736.
[8]
Elmendorf H, Bangs J, Haldar K (1992) Synthesis and secretion of proteins by released malarial parasites. Mol Biochem Parasitol 52: 215–230.
[9]
Lieber M, Steck T (1982) Dynamics of the holes in human erythrocyte membrane ghosts. J Biol Chem 257: 11660–11666.
[10]
Lieber M, Steck T (1982) A description of the holes in human erythrocyte membrane ghosts. J Biol Chem 257: 11651–11659.
[11]
Trager W, Jensen JB (1976) Human malaria parasites in continuous culture. Science 193: 673–675.
[12]
Haldar K, Elmendorf HG, Das A, Li WL, Ferguson DJ, et al. (1994) In vitro secretory assays with erythrocyte-free malaria parasites. Methods Cell Biol 45: 221–246.
[13]
Lopez-Estrano C, Bhattacharjee S, Harrison T, Haldar K (2003) Cooperative domains define a unique host cell-targeting signal in -infected erythrocytes. Proc Natl Acad Sci U S A 100: 12402–12407.
[14]
Tiffert T, Ginsburg H, Krugliak M, Elford BC, Lew VL (2000) Potent antimalarial activity of clotrimazole in in vitro cultures of . Proc Natl Acad Sci U S A 97: 331–336.
[15]
Pastor-Barriuso R, Guallar E, Coresh J (2003) Transition models for change-point estimation in logistic regression. Stat Med 22: 1141–1162.
[16]
Martin SK, Oduola AM, Milhous WK (1987) Reversal of chloroquine resistance in by verapamil. Science 235: 899–901.
[17]
Tallarida RJ (2001) Drug synergism: Its detection and applications. Pharmacology and experimental therapeutics 298: 865–872.
[18]
Bhattacharjee S, Hiller NL, Liolios K, Kanneganti T, Young C, et al. (2006) The malarial host-targeting signal is conserved in the Irish potato famine pathogen. PLoS Pathog 2: e50.. doi:10.1371/journal.ppat.0020050.
[19]
Peters W (1980) Chemotherapy of malaria. In: Kreier JP, editor. Malaria: Epidemiology, chemotherapy, morphology and metabolism. New York: Academic Press. pp. 160–163.
[20]
Petersen A, Kristensen SR, Jacobsen JP, Horder M (1990) 31P-NMR measurements of ATP, ADP, 2,3-diphosphoglycerate and Mg2+ in human erythrocytes. Biochim Biophys Acta 1035: 169–174.
[21]
Gupta RK, Benovic JL, Rose ZB (1978) The determination of the free magnesium level in the human red blood cell by 31P NMR. J Biol Chem 253: 6172–6176.
[22]
Sager G (1982) Receptor binding sites for beta-adrenergic ligands on human erythrocytes. Biochem Pharmacol 31: 99–104.
[23]
Sager G, Jacobsen S (1985) Effect of plasma on human erythrocyte beta-adrenergic receptors. Biochem Pharmacol 34: 3767–3771.
[24]
Mazzoni MR, Taddei S, Giusti L, Rovero P, Galoppini C, et al. (2000) A Gas carboxyl-terminal peptide prevents Gs activation by the A2A adenosine receptor. Mol Pharmacol 58: 226–236.
[25]
Wagner MA, Andemariam B, Desai SA (2003) A two-compartment model of osmotic lysis in -infected erythrocytes. Biophys J 84: 116–123.
White NJ (2004) Antimalarial drug resistance. J Clin Invest 113: 1084–1092.
[28]
Krishna S, Woodrow CJ, Staines HM, Haynes RK, Mercereau-Puijalon O (2006) Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance. Trends Mol Med 12: 200–205.
[29]
Paradiso-Hardy FL, Walker SE, Bowles SK (1998) Steady-state pharmacokinetics of propranolol enantiomers in healthy male volunteers. Int J Clin Pharmacol Ther 36: 370–375.
[30]
Prakash C, Koshakji RP, Wood AJ, Blair IA (1989) Simultaneous determination of propranolol enantiomers in plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Sci 78: 771–775.
[31]
Lin JH (1998) Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 26: 1202–1212.
[32]
Lin JH (1995) Species similarities and differences in pharmacokinetics. Drug Metab Dispos 23: 1008–1021.
[33]
Steck T, Kant J (1974) Preparation of impermeable ghosts and inside-out vesicles from human erythrocyte membranes. Methods Enzymol 31: 172–180.
[34]
Dluzewski AR, Rangachari K, Wilson RJ, Gratzer WB (1981) Entry of malaria parasites into resealed ghosts of human and simian erythrocytes. Br J Haematol 49: 97–101.
[35]
Dluzewski AR, Rangachari K, Wilson RJ, Gratzer WB (1983) Properties of red cell ghost preparations susceptible to invasion by malaria parasites. Parasitology 87: 429–438.
[36]
Olson JA, Kilejian A (1982) Involvement of spectrin and ATP in infection of resealed erythrocyte ghosts by the human malarial parasite, . J Cell Biol 95: 757–762.
[37]
Pei X, An X, Guo X, Tarnawski M, Coppel R, et al. (2005) Structural and functional studies of interaction between knob-associated histidine-rich protein (KAHRP) and erythrocyte spectrin. J Biol Chem 280: 31166–31171.
[38]
Gutiérrez Millán C, Zarzuelo Castaneda A, Sayalero Marinero ML, Lanao JM (2004) Factors associated with the performance of carrier erythrocytes obtained by hypotonic dialysis. Blood Cells Mol Dis 33: 132–140.
[39]
Dluzewski AR, Rangachari K, Wilson RJ, Gratzer WB (1983) A cytoplasmic requirement of red cells for invasion by malarial parasites. Mol Biochem Parasitol 9: 145–160.
[40]
Rangachari K, Dluzewski AR, Wilson RJ, Gratzer WB (1987) Cytoplasmic factor required for entry of malaria parasites into RBCs. Blood 70: 77–82.
[41]
Neves SR, Ram PT, Iyengar R (2002) G protein pathways. Science 296: 1636–1639.
[42]
Hiller NL, Akompong T, Morrow JS, Holder AA, Haldar K (2003) Identification of a stomatin orthologue in vacuoles induced in human erythrocytes by malaria parasites. A role for microbial raft proteins in apicomplexan vacuole biogenesis. J Biol Chem 278: 48413–48421.
[43]
Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, et al. (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11: 1170–1172.
[44]
Dickson M, Gagnon JP (2004) Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 3: 417–429.
[45]
Beers MH, Berkow R, editors. (2006) The Merck manual of diagnosis and therapy. 18th edition. Rahway, New Jersey: Merck Research Laboratories. Available at http://www.merck.com/media/mmpe/pdf/Tabl？e_071–6.pdf. Accessed 25 November 2006.
[46]
Supanaranond W, Davis TM, Pukrittayakamee S, Nagachinta B, White NJ (1993) Abnormal circulatory control in falciparum malaria: The effects of antimalarial drugs. Eur J Clin Pharmacol 44: 325–329.
[47]
Loon NR, Wilcox CS, Folger W (1986) Orthostatic hypotension due to quinidine and propranolol. Am J Med 81: 1101–1104.
[48]
Richards DA, Woodings EP, Maconochie JG (1977) Comparison of the effects of labetalol and propranolol in healthy men at rest and during exercise. Br J Clin Pharmacol 4: 15–21.
[49]
O'Connor PC, Finch MJ, Harron DW, Meredith PA, McDevitt DG, et al. (1985) Comparison of the haemodynamic effects of bucindolol, propranolol and pindolol in healthy volunteers. Br J Clin Pharmacol 20: 659–667.
[50]
Mansor SM, Taylor TE, McGrath CS, Edwards G, Ward SA, et al. (1990) The safety and kinetics of intramuscular quinine in Malawian children with moderately severe falciparum malaria. Trans R Soc Trop Med Hyg 84: 482–487.
[51]
Halmagyi DF, Gillett DJ, Irving MH (1967) Partial and “complete” adrenergic blockade in posthemorrhagic shock. J Appl Physiol 22: 487–494.
[52]
Luchette FA, Robinson BR, Friend LA, McCarter F, Frame SB, et al. (1999) Adrenergic antagonists reduce lactic acidosis in response to hemorrhagic shock. J Trauma 46: 873–880.
[53]
Motulsky HJ, Maisel AS, Snavely MD, Insel PA (1984) Quinidine is a competitive antagonist at alpha 1- and alpha 2-adrenergic receptors. Circ Res 55: 376–381.
[54]
Touze JE, Heno P, Fourcade L, Deharo JC, Thomas G, et al. (2002) The effects of antimalarial drugs on ventricular repolarization. Am J Trop Med Hyg 67: 54–60.
[55]
[No authors listed]. (1990) Mefloquine for malaria. Med Lett Drugs Ther 31: 13–14.
[56]
Bustos MD, Gay F, Diquet B, Thomare P, Warot D (1994) The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects. Trop Med Parasitol 45: 83–86.
[57]
Ngouesse B, Basco LK, Ringwald P, Keundjian A, Blackett KN (2000) Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients. Am J Trop Med Hyg 65: 711–716.
[58]
Ribeiro IR, Olliaro P (1998) Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med Trop (Mars) 58: 50–53.
[59]
Gupta RK, Van Vugt M, Paiphun L, Slight T, Looareesuwan S, et al. (2005) Short report: No evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate. Am J Trop Med Hyg 73: 267–268.
